Document #13

MEDICINE...
DESIGNED FOR HEALTH...
PRODUCED WITH CARE

THE UPJOHN COMPANY

KALAMAZOO, MICHIGAN 49001
TELEPHONE (616) 345-3571

Office of
E. KEITH BOROEN, M. D.
Medical Chief
Diabetes Products

July 8, 1969

Max Miller, M.D.
Professor of Medicine
University Hospitals of Cleveland
2065 Adelbert Road
Cleveland, Ohio 44106

Dear Dr. Miller:

I should like to thank you and the members of the UGDP who attended the June 29th meeting for the opportunity to discuss the UGDP study, particularly as it relates to tolbutamide.

I was very pleased with your opening comments at the meeting, in which you indicated that this was the opening of lines of communication and I look forward to further exchanges.

I shall look forward to hearing the comments of the group relative to the points we raised in our initial review. As I indicated to you previously, we will, in the near future, be submitting to you a much more specific set of questions for your consideration and answer. I should, however, at this time like to raise one further question and hope that we may be able to obtain the answer in short order.

I would like to know whether subjects, particularly in the tolbutamide and placebo group who were placed on medication other than tolbutamide or placebo, were analyzed in the most recent data as part of the placebo or tolbutamide group.

If they were, I should like to obtain the answers to the following questions:

1. Of the subjects who died, how many were on either tolbutamide or placebo at the time of their death?

2. Of the subjects who were not on either the tolbutamide or placebo at the time of death, what was their therapy at the time of their death and how long had they been on it?

cont/...

3. Of the subjects who were on tolbutamide or placebo at the time of their death, was there a period of time during the study that they were not on tolbutamide or placebo, and if so how long?

4. Of all subjects in the tolbutamide group, how many subjects are no longer on tolbutamide and for what period of time have they been off tolbutamide?

5. For all subjects on placebo, how many of the subjects are no longer on placebo and for what period of time have they been off placebo?

6. For all subjects in the tolbutamide and placebo groups, who are off tolbutamide and placebo, what antidiabetic treatment are they on?

7. For all subjects on tolbutamide or placebo at the present time, how many subjects have been on some other therapy during the course of the study and for what period of time have they been on this therapy?

I would very much appreciate knowing the answers to these questions and shall look forward to hearing from you.

Again, let me express my thanks for the opportunity to meet with the UGDP group.

Sincerely,

E. Keith Borden, M.D.

/so

cc: Drs. Boshell, Goetz, Goldner, Kilo, Klimt, Knatterud, Knowles, Meinert, Osborne, Prout, Reeves & Schwartz